Member Info for SteveV

Looks like on the chart we have just broken out to the upside of a wedge formation.
Going up from here !!

Well time will tell. I am not that hopeful really. A "restructuring" can often mean shareholders come out with very little.
E.g. GKP shareholders got 5% back.

We don't know really do we because we don't know what the current production capacity is running at.
If NCYT is making 16miliion kits a month and selling 15 million we are doing great and they are stock piling a million a month for immediate despatch if/when required.

Hey HarChris, yes you are quite right the Lamp test is NOT an antigen. It is a cheaper, quicker PCR type test(no doubt not quite as accurate as the PCR) . I think NCYT have developed it to compete with the Antigen.(maybe for mass testing).
So whilst not antigen, it is designed and positioned, I think, to compete in that segment of the market.

Well actually, we do have a LAMP antigen test, AND an LFT anitbody test coming out in Jan. as well as our current world beating PCR.

So I think we are covering all bases.
I would also imagine that our new tests are top notch and will be widely in demand.

I think it is obvious that Blackrock have identified that NCYT is not a fly by night company who will crash and burn post COVID. That has always been the worry with some investors. The sp should now be many multiples higher than is currently if current revenue was in perpetuity.(or even a fraction of)

I think there will be no post COVID. It will be more of a case of learning to live with it, controlling it , as we do with the flu, with vaccine and testing at peak times during the year(winter).

As the vaccine(IF SUCCESSFUL) is rolled out(slowly) testing will always be necessary. As the need for PCR/antigen testing slows(but remains at some level), the need for antiibody testing to monitor those vaccinating increases.

So say for instance, NEXT winter we may have the capacity to vaccinate 30 million people in just the UK, we will need twice as many antibody tests to monitor them.

The rollout of the Q16/32 machines throughout the worlds health systems is surely going to be a permanent resource to health providers. Testing for COVID, testing to distinguish between COVID and the flu, testing for antibodies to see is the vaccine has been effective. Testing ,testing, testing. in perpetuity using Q16/32 machines. I think that is what Blackrock have come to the conclusion of. I am inclined to agree.

Is there any info that we are DEFINITELY in the mix for this tender.?

He won't pull the article. He is a freelance journalist who only gets paid per article.
He's probably loving the attention.

I never read newspapers these days. I am not really interested in the opinion from the politically biased press who are masquerading as news outlets.

Yes, we all know that here. Why didn't the Independent journalist checkout the current state of events
before creating an alarmingly provocatively titled piece.

"..Why let facts get in the way of a good story.." That is what a journalist told me once.....Shocking !!!??

He is on twitter if anyone can be bothered to query any of his article.

https://twitter.com/samueljlovett?lang=en

".....The Primerdesign device requires a “multi-pipette” distillation process that sees patient swab samples placed from one solution to another by trained biomedical scientists, before eventually being processed via the machine. .."

Really?? You have to be a BIOMEDICAL SCIENTIST to do a bit of pipetting between test tubes. I would be fairly confident I could manage that with half an hours training.

Earth 70000,
Are you really sure that is your view. Don't you have any elderly/vulnerable relatives.

Yes I do remember him a Gulf keystone. He took a huge pay check for doing a bit of work on a Sunday.
I think he was given the title of Chief of strategy , or something like that.
It didn't end well for shareholders who lost 95% of their investment.

Any analysis come with that, or workings out, to show how they arrived at their figure?

Still waiting for the Oddo note.

So you have initially given the first vaccines to the vulnerable, the old and NHS/care home staff.
Surely you are going to have to test EVERYONE you gave the vaccine to to see if they have the antibody.
Millions of tests required !

I see they have got the production capacity at 750 per month for the Q machines not the 1500 as others have.

Q16/32 machines in every hospital, care home, airport, school, university, business, GP surgery...I could go on....

Quite a few directors buys around £3 in May June, only to see the sp drop back. Then look what happened.

I think what will happen after spring time governments will have to be planning for next winter. Sure a good supply of vaccines will be secured but also a proper testing infrastructure. I can imagine very large orders for Q16/32 machines. Most hospitals will need multiple machines, and maybe every care home especially with the easy to use Promate tests.
The government will get hammered if they mess winter 21/22 up.

This is what our CEO said of the £406m DHSC contract.
"...The contract which was announced this morning is not something which suddenly occurs. It has been negotiated over a significant period of time..."

So what else have NCYT been negotiating which prompts the CEO to buy £500k worth of stock?